Nurix Therapeutics held its 2026 Annual Meeting on May 15, 2026, where stockholders elected three Class III directors, ratified the auditor, and approved executive compensation on an advisory basis.
Key takeaways
All three director nominees were elected with majority support; Arthur T. Sands received 63.6M votes for.
PricewaterhouseCoopers LLP was ratified as independent auditor for fiscal 2026 with 83.6M votes for.
Executive compensation was approved on a non-binding advisory basis with 72.5M votes for.
Broker non-votes were 3.8M for director elections and the say-on-pay proposal.
Quorum was achieved with 83.7M shares present, representing 80.98% of voting power.